BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Nitzan-Luques A, Slae M, Zugayar D, Dixon BP, Meir K, Volovelsky O. Neonatal thrombotic microangiopathy secondary to factor I variant with Hirschsprung disease. J Nephrol 2021;34:241-5. [PMID: 32514992 DOI: 10.1007/s40620-020-00766-5] [Reference Citation Analysis]
3 Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol 2013;28:827-30. [PMID: 23389237 DOI: 10.1007/s00467-013-2416-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
4 Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Brüggemann R, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment. Clin Pharmacol Ther 2017;102:671-8. [DOI: 10.1002/cpt.686] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
5 Abu Daher G, Aoun B, Jaafar F, Khafaja S, Sanjad S. Norovirus: a novel etiologic agent in hemolytic uremic syndrome in an infant. BMC Nephrol 2019;20:247. [PMID: 31277594 DOI: 10.1186/s12882-019-1427-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014;29:1895-902. [PMID: 23843163 DOI: 10.1007/s00467-013-2561-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
7 Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab: An infant with eculizumab-resistant aHUS. Nephrology 2016;21:261-5. [DOI: 10.1111/nep.12582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Raina R, Chauvin A, Fox K, Kesav N, Ascha M, Vachharajani TJ, Krishnappa V. Effect of Immunosuppressive Therapy on the Occurrence of Atypical Hemolytic Uremic Syndrome in Renal Transplant Recipients. Ann Transplant 2018;23:631-8. [PMID: 30190449 DOI: 10.12659/AOT.909781] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
10 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society: aHUS diagnostic guidelines. Pediatr Int 2014;56:1-5. [DOI: 10.1111/ped.12274] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
11 Loos S, Ahlenstiel T, Kranz B, Staude H, Pape L, Härtel C, Vester U, Buchtala L, Benz K, Hoppe B, Beringer O, Krause M, Müller D, Pohl M, Lemke J, Hillebrand G, Kreuzer M, König J, Wigger M, Konrad M, Haffner D, Oh J, Kemper MJ. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012;55:753-9. [PMID: 22670043 DOI: 10.1093/cid/cis531] [Cited by in Crossref: 100] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
12 Kim JJ, Goodship THJ, Tizard J, Inward C. Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatr Nephrol 2011;26:2073-6. [DOI: 10.1007/s00467-011-1944-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
13 Hildebrand AM, Huang SS, Clark WF. Plasma Exchange for Kidney Disease: What Is the Best Evidence? Advances in Chronic Kidney Disease 2014;21:217-27. [DOI: 10.1053/j.ackd.2014.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
14 Davin JC, Groothoff J, Gracchi V, Bouts A. Long-term renal function under plasma exchange in atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1915-6. [PMID: 21647646 DOI: 10.1007/s00467-011-1925-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
15 Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, Winters JL. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apheresis 2014;29:148-67. [DOI: 10.1002/jca.21302] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
16 Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015;29:191-204. [PMID: 25483393 DOI: 10.1016/j.blre.2014.11.001] [Cited by in Crossref: 155] [Cited by in F6Publishing: 138] [Article Influence: 19.4] [Reference Citation Analysis]
17 Hisano M, Ashida A, Nakano E, Suehiro M, Yoshida Y, Matsumoto M, Miyata T, Fujimura Y, Hattori M. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy: Eculizumab for aHUS. Pediatr Int 2015;57:313-7. [DOI: 10.1111/ped.12469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
18 Lopes da Silva R. Viral-associated thrombotic microangiopathies. Hematol Oncol Stem Cell Ther 2011;4:51-9. [PMID: 21727765 DOI: 10.5144/1658-3876.2011.51] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
19 Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, Bedrosian CL, Faas SJ. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015;125:3253-62. [PMID: 25833956 DOI: 10.1182/blood-2014-09-600411] [Cited by in Crossref: 109] [Cited by in F6Publishing: 96] [Article Influence: 15.6] [Reference Citation Analysis]
20 Kristjansson RP, Oddsson A, Helgason H, Sveinbjornsson G, Arnadottir GA, Jensson BO, Jonasdottir A, Jonasdottir A, Bragi Walters G, Sulem G, Oskarsdottir A, Benonisdottir S, Davidsson OB, Masson G, Magnusson OT, Holm H, Sigurdardottir O, Jonsdottir I, Eyjolfsson GI, Olafsson I, Gudbjartsson DF, Thorsteinsdottir U, Sulem P, Stefansson K. Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase. Nat Commun 2016;7:10572. [PMID: 26838040 DOI: 10.1038/ncomms10572] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
21 Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 2012;5:34-6. [PMID: 26069744 DOI: 10.1093/ndtplus/sfr174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
22 Liebau MC. An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr 2014;2:68. [PMID: 25050320 DOI: 10.3389/fped.2014.00068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
23 Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C. Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013;54:84-8. [PMID: 23220071 DOI: 10.1016/j.molimm.2012.10.044] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
24 Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91. [PMID: 28899876 DOI: 10.1136/archdischild-2016-311377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
25 Vitkauskaitė M, Vinikovas A, Miglinas M, Rimševičius L, Čerkauskaitė A, Mačionienė E, Ašakienė E. Complement inhibitor eculizumab in thrombotic microangiopathy: Single‐center case series. Clinical Case Reports 2022;10. [DOI: 10.1002/ccr3.5573] [Reference Citation Analysis]
26 Besbas N, Gulhan B, Soylemezoglu O, Ozcakar ZB, Korkmaz E, Hayran M, Ozaltin F. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol. 2017;18:6. [PMID: 28056875 DOI: 10.1186/s12882-016-0420-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
27 Loirat C, Saland J, Bitzan M. Management of hemolytic uremic syndrome. Presse Med. 2012;41:e115-e135. [PMID: 22284541 DOI: 10.1016/j.lpm.2011.11.013] [Cited by in Crossref: 69] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
28 Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, van den Heuvel LP, Mollnes TE. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clinical Immunology 2015;160:237-43. [DOI: 10.1016/j.clim.2015.05.018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
29 Cho H. Complement regulation: physiology and disease relevance. Korean J Pediatr 2015;58:239-44. [PMID: 26300937 DOI: 10.3345/kjp.2015.58.7.239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
30 Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 2015;181:306-13. [PMID: 25079699 DOI: 10.1111/cei.12426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
31 Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, Grovetti E, Tedeschi S, Salardi S, Cresseri D, Messa P, Ardissino G. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014;12:1440-8. [DOI: 10.1111/jth.12615] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
32 Kerr H, Richards A. Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome. Immunobiology 2012;217:195-203. [PMID: 21855165 DOI: 10.1016/j.imbio.2011.07.028] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
33 Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial 2019;23:4-21. [PMID: 30294946 DOI: 10.1111/1744-9987.12763] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
34 Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation–associated thrombotic microangiopathy. Blood 2011;118:1452-62. [DOI: 10.1182/blood-2011-02-321315] [Cited by in Crossref: 193] [Cited by in F6Publishing: 163] [Article Influence: 17.5] [Reference Citation Analysis]
35 Yang B, Sylvius N, Luo J, Yang C, Da Z, Crotty C, Nicholson ML. Identifying Biomarkers from Transcriptomic Signatures in Renal Allograft Biopsies Using Deceased and Living Donors. Front Immunol 2021;12:657860. [PMID: 34276651 DOI: 10.3389/fimmu.2021.657860] [Reference Citation Analysis]
36 Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012;27:2327-31. [PMID: 22903728 DOI: 10.1007/s00467-012-2283-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
37 Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011;48:1631-42. [PMID: 21549429 DOI: 10.1016/j.molimm.2011.04.014] [Cited by in Crossref: 203] [Cited by in F6Publishing: 188] [Article Influence: 18.5] [Reference Citation Analysis]
38 Chapin J, Weksler B, Magro C, Laurence J. Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012;157:772-4. [PMID: 22409250 DOI: 10.1111/j.1365-2141.2012.09084.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 6.7] [Reference Citation Analysis]
39 Kaplan BS, Ruebner RL, Copelovitch L. Eculizumab treatment of atypical hemolytic uremic syndrome. Expert Opinion on Orphan Drugs 2012. [DOI: 10.1080/21678707.2013.750579] [Reference Citation Analysis]
40 Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L. Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011;26:1919-20. [PMID: 21643943 DOI: 10.1007/s00467-011-1929-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
41 Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the joint committee of the Japanese society of nephrology and the Japan pediatric society. Clin Exp Nephrol 2014;18:4-9. [DOI: 10.1007/s10157-013-0911-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
42 Keir LS, Marks SD, Kim JJ. Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies. Drug Des Devel Ther 2012;6:195-208. [PMID: 22888220 DOI: 10.2147/DDDT.S25757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
43 Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:783-9. [DOI: 10.1007/s00467-014-3003-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
44 Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab. Nephrol Dial Transplant 2014;29 Suppl 4:iv131-41. [PMID: 25165180 DOI: 10.1093/ndt/gfu235] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
45 Brandstätter H, Schulz P, Polunic I, Kannicht C, Kohla G, Römisch J. Purification and biochemical characterization of functional complement factor H from human plasma fractions: Factor H purification from human plasma fractions. Vox Sanguinis 2012;103:201-12. [DOI: 10.1111/j.1423-0410.2012.01610.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ricklin D, Lambris JD. Progress and Trends in Complement Therapeutics. Adv Exp Med Biol 2013;735:1-22. [PMID: 22990692 DOI: 10.1007/978-1-4614-4118-2_1] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 9.3] [Reference Citation Analysis]
47 Mahmoudi M, Nilsson PH, Mollnes TE, Roos D, Sullivan KE. Complement Deficiencies. In: Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary Immunodeficiency Diseases. Berlin: Springer Berlin Heidelberg; 2017. pp. 437-60. [DOI: 10.1007/978-3-662-52909-6_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Keating GM. Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs Ther Perspect 2014;30:166-72. [DOI: 10.1007/s40267-014-0120-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Kościelska-Kasprzak K, Bartoszek D, Myszka M, Zabińska M, Klinger M. The complement cascade and renal disease. Arch Immunol Ther Exp (Warsz) 2014;62:47-57. [PMID: 24030732 DOI: 10.1007/s00005-013-0254-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
50 Asif A, Vachharajani T, Salman L, Nayer A. A Simplified Approach to the Diagnosis of Atypical HUS: Clinical Considerations and Practical Implications. TOUNJ 2014;7:91-4. [DOI: 10.2174/1874303x01407010091] [Cited by in Crossref: 4] [Article Influence: 0.5] [Reference Citation Analysis]
51 Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan: Natural history of Upshaw-Schulman syndrome. Journal of Thrombosis and Haemostasis 2011;9:283-301. [DOI: 10.1111/j.1538-7836.2011.04341.x] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 11.0] [Reference Citation Analysis]
52 Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab 2021;10:225-30. [PMID: 34765894 DOI: 10.1097/XCE.0000000000000247] [Reference Citation Analysis]
53 Picard C, Burtey S, Bornet C, Curti C, Montana M, Vanelle P. Pathophysiology and treatment of typical and atypical hemolytic uremic syndrome. Pathologie Biologie 2015;63:136-43. [DOI: 10.1016/j.patbio.2015.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
54 Zimbudzi E. Overcoming technical challenges when treating atypical hemolytic uremic syndrome with therapeutic plasma exchange. Int J Nephrol Renovasc Dis 2013;6:245-8. [PMID: 24277990 DOI: 10.2147/IJNRD.S53074] [Reference Citation Analysis]
55 Waters A. Optimizing treatment strategies in paediatric atypical hemolytic uremic syndrome. Pediatr Nephrol 2011;26:1917-8. [DOI: 10.1007/s00467-011-1930-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
56 Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Yüksel S, Işık Gönül İ, Canpolat N, Gökçe İ, Özlü SG, Özçakar ZB, Ozaltin F, Söylemezoğlu O. Renal Biopsy Prognostic Findings in Children With Atypical Hemolytic Uremic Syndrome. Pediatr Dev Pathol 2020;23:362-71. [PMID: 32406813 DOI: 10.1177/1093526620925947] [Reference Citation Analysis]
58 McCoy N, Weaver DJ Jr. Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities. BMC Pediatr 2014;14:278. [PMID: 25373393 DOI: 10.1186/1471-2431-14-278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Wanchoo R, Bayer RL, Bassil C, Jhaveri KD. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments. Am J Kidney Dis 2018;72:857-65. [PMID: 30146419 DOI: 10.1053/j.ajkd.2018.06.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
60 Das A, Dean A, Clay T. Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma. BMJ Case Rep 2019;12:e228363. [PMID: 30962211 DOI: 10.1136/bcr-2018-228363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Nester C, Stewart Z, Myers D, Jetton J, Nair R, Reed A, Thomas C, Smith R, Brophy P. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2011;6:1488-1494. [PMID: 21617085 DOI: 10.2215/cjn.10181110] [Cited by in Crossref: 91] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
62 Rafiq A, Tariq H, Abbas N, Shenoy R. Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 2015;16:109-14. [PMID: 25708146 DOI: 10.12659/AJCR.892907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
63 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
64 Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 1: Liver-based metabolic disorders without liver lesions. Clin Res Hepatol Gastroenterol. 2011;35:194-203. [PMID: 21376697 DOI: 10.1016/j.clinre.2011.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
65 Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? Hematology 2012;2012:617-25. [DOI: 10.1182/asheducation.v2012.1.617.3798924] [Cited by in Crossref: 66] [Article Influence: 6.6] [Reference Citation Analysis]
66 Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, Ohta T, Yoshida Y, Terano C, Iwasa T, Kubota W, Takada H, Hara T, Fujimura Y, Ito S. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:265-72. [DOI: 10.1007/s10157-015-1142-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
67 Nayer A, Asif A. Atypical hemolytic-uremic syndrome: a clinical review. Am J Ther. 2016;23:e151-e158. [PMID: 24681522 DOI: 10.1097/mjt.0b013e31829b59dc] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
68 Gnappi E, Allinovi M, Vaglio A, Bresin E, Sorosina A, Pilato FP, Allegri L, Manenti L. Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case. Pediatr Nephrol 2012;27:1995-9. [DOI: 10.1007/s00467-012-2210-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
69 Ohta T, Urayama K, Tada Y, Furue T, Imai S, Matsubara K, Ono H, Sakano T, Jinno K, Yoshida Y, Miyata T, Fujimura Y. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 2015;30:603-8. [PMID: 25318620 DOI: 10.1007/s00467-014-2975-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
70 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
71 Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013;122:2003-7. [PMID: 23814021 DOI: 10.1182/blood-2013-05-501445] [Cited by in Crossref: 165] [Cited by in F6Publishing: 139] [Article Influence: 18.3] [Reference Citation Analysis]
72 Caillaud C, Zaloszyc A, Licht C, Pichault V, Frémeaux-Bacchi V, Fischbach M. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-61. [PMID: 26399238 DOI: 10.1007/s00467-015-3207-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
73 Schmidt CQ, Slingsby FC, Richards A, Barlow PN. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr Purif 2011;76:254-63. [PMID: 21146613 DOI: 10.1016/j.pep.2010.12.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
74 Besbas N, Gulhan B, Karpman D, Topaloglu R, Duzova A, Korkmaz E, Ozaltin F. Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. Pediatr Nephrol 2013;28:155-8. [PMID: 22956028 DOI: 10.1007/s00467-012-2296-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
75 Tambourgi DV, van den Berg CW. Animal venoms/toxins and the complement system. Mol Immunol 2014;61:153-62. [PMID: 24998802 DOI: 10.1016/j.molimm.2014.06.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
76 Kalambay J, Zaman R, Zaman M. Atypical Hemolytic Uremic Syndrome Presenting as Pre-eclampsia in a 24-year-old Woman with Chronic Kidney Disease: Pathogenesis and Genetics. Cureus 2018;10:e3358. [PMID: 30510868 DOI: 10.7759/cureus.3358] [Reference Citation Analysis]
77 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
78 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
79 Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125:3860-3867. [PMID: 25784681 DOI: 10.1182/blood-2014-11-551580] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 12.4] [Reference Citation Analysis]